The Washington Post @washingtonpost
An experimental Alzheimer’s drug moderately slowed the effects of the disease but was linked to patient safety risks that warrant longer clinical trials, according to a study published late Tuesday. https://t.co/R4uxdpJryR — PolitiTweet.org